Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julien Racle

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Nature Biotechnology|October 16, 2019
Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomesJulien Racle, Justine Michaux, Georg Alexander Rockinger, et al.
Immunity|April 6, 2023
Machine learning predictions of MHC-II specificities reveal alternative binding mode of class II epitopesJulien Racle, Philippe Guillaume, Julien Schmidt, et al.
Science Advances|March 5, 2025
Donor HLA-DQ genetic and functional divergence affect the control of BK polyoma virus infection after kidney transplantationMathieu F Chevalier, Vincent Allain, Julien Gras, et al.
Cell Reports. Medicine|March 5, 2021
Prediction of neo-epitope immunogenicity reveals TCR recognition determinants and provides insight into immunoeditingJulien Schmidt, Angela R Smith, Morgane Magnin, et al.
Frontiers in Immunology|August 24, 2019
A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma-A Proof of Antigen Discovery Feasibility in Three PatientsMichal Bassani-Sternberg, Antonia Digklia, Florian Huber, et al.
The Journal of Clinical Investigation|June 27, 2017
ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrenceMathieu F Chevalier, Sara Trabanelli, Julien Racle, et al.
Journal for Immunotherapy of Cancer|November 19, 2019
Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatmentAlice Newey, Beatrice Griffiths, Justine Michaux, et al.
Cancer Cell|April 25, 2020
Cathepsin S Regulates Antigen Processing and T Cell Activity in Non-Hodgkin LymphomaElie Dheilly, Elena Battistello, Natalya Katanayeva, et al.
Science Advances|June 27, 2025
Engineered CD4 TCR T cells with conserved high-affinity TCRs targeting NY-ESO-1 for advanced cellular therapies in cancerMargaux Saillard, Mara Cenerenti, Patrick Reichenbach, et al.
Nature Communications|March 17, 2018
Sensitive and frequent identification of high avidity neo-epitope specific CD8 <sup>+</sup> T cells in immunotherapy-naive ovarian cancerSara Bobisse, Raphael Genolet, Annalisa Roberti, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Nature Biotechnology|October 16, 2019
Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomesJulien Racle, Justine Michaux, Georg Alexander Rockinger, et al.
Immunity|April 6, 2023
Machine learning predictions of MHC-II specificities reveal alternative binding mode of class II epitopesJulien Racle, Philippe Guillaume, Julien Schmidt, et al.
Science Advances|March 5, 2025
Donor HLA-DQ genetic and functional divergence affect the control of BK polyoma virus infection after kidney transplantationMathieu F Chevalier, Vincent Allain, Julien Gras, et al.
Cell Reports. Medicine|March 5, 2021
Prediction of neo-epitope immunogenicity reveals TCR recognition determinants and provides insight into immunoeditingJulien Schmidt, Angela R Smith, Morgane Magnin, et al.
Frontiers in Immunology|August 24, 2019
A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma-A Proof of Antigen Discovery Feasibility in Three PatientsMichal Bassani-Sternberg, Antonia Digklia, Florian Huber, et al.
The Journal of Clinical Investigation|June 27, 2017
ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrenceMathieu F Chevalier, Sara Trabanelli, Julien Racle, et al.
Journal for Immunotherapy of Cancer|November 19, 2019
Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatmentAlice Newey, Beatrice Griffiths, Justine Michaux, et al.
Cancer Cell|April 25, 2020
Cathepsin S Regulates Antigen Processing and T Cell Activity in Non-Hodgkin LymphomaElie Dheilly, Elena Battistello, Natalya Katanayeva, et al.
Science Advances|June 27, 2025
Engineered CD4 TCR T cells with conserved high-affinity TCRs targeting NY-ESO-1 for advanced cellular therapies in cancerMargaux Saillard, Mara Cenerenti, Patrick Reichenbach, et al.
Nature Communications|March 17, 2018
Sensitive and frequent identification of high avidity neo-epitope specific CD8 <sup>+</sup> T cells in immunotherapy-naive ovarian cancerSara Bobisse, Raphael Genolet, Annalisa Roberti, et al.
Pageof 4